Sai Pingali, MD
Hematology & Oncology · Houston, TXNPI 1104089036
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,390 of the $22,954 with a category attached, or 75.8%. Gilead accounts for 74.6% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $12,153, 2.3 times the $5,281 reported in 2019.
Across 72 payments — averaging $318.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$17K
- Incyte Corporation$3K
- Seagen Inc.$2K
- AstraZeneca$258
- National Marrow Donor Program$215
- Pfizer$179
- plus $806 from 21 others
Across 19 payments — averaging $9933.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$76K
- AbbVie$43K
- Bristol Myers Squibb$26K
- Acrotech Biopharma Inc.$26K
- Genentech, Inc.$18K
What the payments were for
- Consulting fees$17,39076%
- Speaking & faculty fees$1,5007%
- Travel & lodging$1,9999%
- Food & beverage$2,0339%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 20 | $17,125 |
| Incyte Corporation | 3 | $2,819 |
| Seagen Inc. | 3 | $1,553 |
| AstraZeneca | 3 | $258 |
| National Marrow Donor Program | 1 | $215 |
| Pfizer | 6 | $179 |
| Novartis | 6 | $127 |
| Amgen | 4 | $95 |
| Astellas Pharma US Inc | 3 | $71 |
| Adaptive Biotechnologies Corporation | 2 | $67 |
| Bristol Myers Squibb | 2 | $52 |
| Merck | 2 | $38 |
| Beigene USA, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Lilly USA, LLC | 1 | $31 |
| Johnson & Johnson | 1 | $30 |
| CTI Biopharma Corp. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| AbbVie | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| GSK | 1 | $22 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Genentech USA, Inc. | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,954 in reported general payments places this provider in the 80th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ScemblixAsciminib Hydrochloride | 13 | $963,525 |
| RevlimidLenalidomide | 30 | $551,163 |
| Lenalidomide | 20 | $350,460 |
| BrukinsaZanubrutinib | 22 | $314,509 |
| JakafiRuxolitinib Phosphate | 16 | $244,804 |
| BosulifBosutinib | 15 | $156,922 |
| EliquisApixaban | 13 | $7,578 |
| ValacyclovirValacyclovir Hcl | 105 | $5,752 |
| Cyclosporine ModifiedCyclosporine, Modified | 20 | $4,300 |
| TrexallMethotrexate Sodium | 14 | $2,958 |
| Cefpodoxime Proxetil | 20 | $2,895 |
| Fluconazole | 35 | $1,101 |
| Ondansetron OdtOndansetron | 49 | $413 |
| Dexamethasone | 21 | $270 |
| Hydrocortisone | 11 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisScemblix | $127 | $963,52513 claims |
| Bristol Myers SquibbRevlimid | $52 | $551,16330 claims |
| Beigene USA, Inc.Brukinsa | $37 | $314,50922 claims |
| Incyte CorporationJakafi | $2,819 | $244,80416 claims |
| PfizerBosulif, Eliquis | $179 | $164,50028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.